Cipla has a closing price of Rs 1472.4, reflecting a percentage change of 1.49% for today. Cipla is currently valued at Rs 1471.80, marking a 1.45% rise today, alongside a volume of 2,397,104 shares ...

After a lengthy questionnaire, our tester was recommended Hims Hard Mints tadalafil (generic for Cialis). Aaron noted that the questionnaire felt very long and didn’t indicate how many questions ...

Cipla Ltd.'s share price rose to become the top gainer on the NSE Nifty 50 index on Tuesday after Kotak Securities upgraded the stock rating to 'buy' from 'add'. The brokerage expects recovery in the ...

Cipla shares rose 2.4 per cent in trade and recorded an intraday high at Rs 1,483.4 per share on BSE. On NSE, 1.022 million shares changed hands, while on BSE 0.019 million shares were traded. Around ...

Cialis and its generic counterpart, tadalafil, have Food and Drug Administration (FDA) approval to treat erectile dysfunction. Learn more about our most trusted places to get this medication ...

Cipla aims to make the drug accessible to all and empower millions to take control of their health with greater ease. ‘A breath of fresh air for #diabetes_management! Inhaled #insulin ...

Mumbai-based pharmaceutical giant Cipla will distribute and market the drug in India. Show Full Article Inhaled from the mouth at the beginning of a meal, Afrezza dissolves rapidly into the lungs and ...

Sensex and Nifty closed flat in cautious trade on Wednesday. In today's session, several stocks such as Reliance Power Ltd, Cipla, PC Jeweller, etc are likely to be in focus due to recent developments ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a ...

New Delhi, Dec 11 (PTI) Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder ...

HSBC has identified its top picks in the Indian pharmaceutical sector, maintaining a "buy" rating on Cipla Ltd., Sun Pharmaceutical Industries Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., and ...